Dr Liz Moore at the conference
Facebook Facebook Share
Posted by Target Ovarian Cancer on Monday 23 July 2018

Earlier this month, our nurse advisers Joan and Val attended the annual meeting of the British Gynaecological Cancer Society (BGCS), the UK’s largest conference dedicated to gynaecological cancer. The conference was attended by over 450 scientists, doctors, nurses and patients. Joan and Val spent the conference discussing about the latest developments in gynae-oncology, and talking to healthcare professionals about the support we offer to them and to women with ovarian cancer.

The conference programme included a wide range of talks from international experts in gynaecological cancer, with a particular emphasis on ovarian cancer. Several clinicians supported by Target Ovarian Cancer, including Professors Iain McNeish and Richard Edmondson, updated delegates on their ground-breaking research programmes and progress in the wider ovarian cancer field. Dr Rebecca Kristeleit, an eminent member of our Scientific Advisory Board, led in putting together a fascinating scientific programme for this highly successful meeting.

Target Ovarian Cancer presented the results of an analysis we had conducted, showing a substantial variation in participation in ovarian cancer clinical trials across the country. In the last year (2017/18), there was a 15-fold difference in participation between different regions across the UK. This means that many women with ovarian cancer in the UK still do not have the opportunity to join a clinical trial.

Out of 180 abstracts submitted to the conference by the research community, seven researchers were selected to give short oral presentations on their research, including Target Ovarian Cancer-funded Dr Elizabeth Moore and Dr Agnieszka Michael. Impressively, from these presentations, Dr Moore was awarded the prestigious prize of best presentation, for her outstanding talk on developing new methods for the earlier and more precise detection of ovarian cancer.

The meeting showcased important updates on results from clinical trials and also provided a valuable opportunity for the gynaecological cancer research community to network, share results, develop new ideas and collaborations.